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Spinal cord injury (SCI) causes loss of neural functions below the level of the lesion due to interruption of 
spinal pathways and secondary neurodegenerative processes. The transplant of neural stem cells (NSCs) is 
a promising approach for the repair of SCI. Reprogramming of adult somatic cells into induced pluripotent 
stem cells (iPSCs) is expected to provide an autologous source of iPSC-derived NSCs, avoiding the immune 
response as well as ethical issues. However, there is still limited information on the behavior and differentia-
tion pattern of transplanted iPSC-derived NSCs within the damaged spinal cord. We transplanted iPSC-derived 
NSCs, obtained from adult human somatic cells, into rats at 0 or 7 days after SCI, and evaluated motor-evoked 
potentials and locomotion of the animals. We histologically analyzed engraftment, proliferation, and differen-
tiation of the iPSC-derived NSCs and the spared tissue in the spinal cords at 7, 21, and 63 days posttransplant. 
Both transplanted groups showed a late decline in functional recovery compared to vehicle-injected groups. 
Histological analysis showed proliferation of transplanted cells within the tissue and that cells formed a mass. 
At the final time point, most grafted cells differentiated to neural and astroglial lineages, but not into oligo-
dendrocytes, while some grafted cells remained undifferentiated and proliferative. The proinflammatory tis-
sue microenviroment of the injured spinal cord induced proliferation of the grafted cells and, therefore, there 
are possible risks associated with iPSC-derived NSC transplantation. New approaches are needed to promote 
and guide cell differentiation, as well as reduce their tumorigenicity once the cells are transplanted at the 
lesion site.
Key words: Spinal cord injury (SCI); Cell therapy; Induced pluripotent stem cells (iPSCs); 
Neural stem cells (NSCs); Differentiation
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INTRODUCTION
Spinal cord injury (SCI) is a devastating event that 
results in neurological deficits due to the damage of the 
spinal cord tissue and the interruption of ascending and 
descending neural pathways. There are no clinical treat-
ments to repair the injured spinal cord. Nonetheless, in 
experimental studies using animal models, cell therapy 
has demonstrated potential beneficial effects, including 
cell replacement by neural stem cell (NSC) transplan-
tation, which has produced some degree of functional 
recovery1,2. The mechanisms of action of the grafted NSCs 
after SCI involve secretion of neuroprotective molecules 
such as neurotrophic factors3,4, which creates a permissive 
environment for axon regeneration5. This results in remy-
elination of spared axons by the newly formed oligoden-
drocytes6 and replacement of dead cells by integration of 
transplanted cells within the remaining tissue for rewiring 
neural networks both caudal and rostral to the injury site7.
Despite the potential of NSC transplants to promote 
substantial recovery in SCI animal models, the transla-
tion of this therapy into the clinic is still a challenge. Until 
it was discovered that somatic cells could be used to pro-
duce induced pluripotent stem cells (iPSCs), NSCs had to 
be obtained from embryonic stem cells (ESCs) or fetal tis-
sue, which involve technical, immunological, and ethical 
problems in the clinical setting. The possibility of obtain-
ing human NSCs from somatic cells through iPSC gen-
eration solved many of the issues that accompanied use 
of embryonic or fetal tissue8. There have been few stud-
ies that focused on the transplantation of iPSC-derived 
NSCs after SCI in animal models. For instance, studies 
in which human iPSC (hiPSC)-derived NSCs were trans-
planted into the injured spinal cord of mice and common 
marmosets showed that the procedure was safe and the 
cells were able to survive, differentiate into neural lin-
eages, integrate within the host neural circuits, and pro-
mote functional recovery1,9. More recently, a study in rats 
with SCI showed that grafted iPSC-derived NSCs were 
able to differentiate into cells of the three neural lineages 
and integrate into the central nervous system (CNS), but, 
contrary to the previous studies, the transplant did not 
lead to improvement in motor function10.
Although iPSCs are becoming a promising source for 
NSC transplantation after SCI, there are still some concerns 
regarding their use for clinical applications, such as the 
potential introduction of transgenes as a result of using viral 
vectors, immunological rejection, and a possible greater risk 
of tumor formation if the somatic cells are not completely 
reprogrammed or remain undifferentiated11. These issues 
need to be addressed by extensive preclinical investigation.
Therefore, it is still uncertain if transplantation of 
iPSC-derived NSCs may be a good therapy for restoring 
the damaged tissue after SCI. Very recent studies have 
also shown controversial outcomes after iPSC-derived 
NSC transplantation in different animal models, from 
absence of functional recovery12 to successful engraft-
ment, differentiation, and recovery of the animals after 
the initial injury13. Thus, the aim of the present study was 
to characterize the differentiation pattern of the iPSC-
derived NSCs once transplanted into the damaged spinal 
cord. We used human NSCs derived from iPSCs gener-
ated from adult fibroblasts, which present advantageous 
features, including the differentiation of transplanted 
stem cells. These cells are able to differentiate into any 
of the three main neural cell types and do not raise com-
patibility issues for application in humans as they can be 
obtained from adult somatic cells, allowing for autolo-
gous transplantation14. We transplanted rats with iPSC-
derived NSCs acutely and subacutely after SCI to study 
how the injury environment affected survival and differ-
entiation of the cells. We observed a detrimental effect on 
the functional recovery of the transplanted animals and 
continuous proliferation as well as noncomplete differen-
tiation of the cells. Therefore, our findings indicate that 
the differentiation pattern of the engrafted cells is crucial 
for a successful functional recovery after SCI and that 
further studies are necessary.
MATERIALS AND METHODS
hiPSC and iPSC-Derived NSC Culture
The procedure for genetic manipulation and genera-
tion of iPSCs from human fibroblasts was reviewed and 
approved by the Ethical Committee of the University 
of Barcelona. Adult human dermal fibroblasts from a 
healthy 48-year-old male volunteer donor, who signed 
a written informed consent form, were subjected to ret-
roviral transduction15 with plasmids encoding for the 
vesicular stomatitis virus glycoprotein (VSV-G) and the 
reprogramming factors octamer-binding transcription 
factor 3/4 (OCT 3/4), (sex determining region Y)-box 
2 (SOX2), Kruppel-like factor 4 (KLF4), and C-MYC, 
and the cells were split into six-well plates (Gibco, 
Thermo Fisher Scientific, Grand Island, NY, USA). After 
3–4 weeks, colonies were then picked and expanded to 
establish 18 hiPSC lines, 3 of which were characterized 
for pluripotency markers, morphology, transgene silenc-
ing, and differentiation. Then the hiPSCs were adapted 
to feeder-free culture conditions on Matrigel (Thermo 
Fisher Scientific, Waltham, MA, USA)-coated plates 
using Essential 8 feeder-free medium (Thermo Fisher 
Scientific). After 1 day of splitting, hiPSCs were induced 
to iPSC-derived NSCs according to Life Technologies 
(now Thermo Fisher Scientific) protocols (www.ther 
mofisher.com) and using Gibco iPSC Neural Induction 
Medium (Gibco, Thermo Fisher Scientific) for 7 days. 
Passage 0 (P0) iPSC-derived NSCs were then ready for 
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cryopreservation, expansion, or differentiation. Cryo-
preserved P0 iPSC-derived NSCs were recovered from 
1-ml vials and plated in Geltrex matrix-coated vessels 
(Gibco). The cells were suspended within complete 
Neural Expansion Medium (Gibco) to a concentration 
of 2 ´ 105 cells/ml. Rho-associated coiled-coil kinase 
(ROCK) inhibitor Y27632 (Sigma-Aldrich, St. Louis, 
MO, USA) at a final concentration of 5 mM was added to 
the cell suspension to prevent cell death. After overnight 
incubation, medium was changed to complete Neural 
Expansion Medium to eliminate the ROCK inhibitor 
Y27632. Neural Expansion Medium without Y27632 
was changed every 2 days.
Electrophysiological In Vitro Study of 
iPSC-Derived NSCs
Standard patch clamp electrophysiological recordings 
were performed with an Axopatch 200B amplifier (Mole-
cular Devices, Sunnyvale, CA, USA) on differentiated 
iPSCs grown on glass coverslips. Membrane currents 
were recorded in the whole-cell configuration with a 
holding voltage of −60 mV, filtered at 2 kHz, digitized at 
10 kHz, and acquired with pClamp 9 software (Molecular 
Devices). Voltage pulses (400 ms) were applied from −100 
to +50 mV in 10-mV increments to record sodium and 
potassium voltage-activated currents. Cells were placed 
in a physiological bath solution: 145 mM NaCl, 5 mM 
KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES (Sigma-
Aldrich) at pH 7.4. Electrodes had a resistance between 
2 and 4 MW when filled with intracellular solution: 140 mM 
KCl, 2.1 mM CaCl2, 2.5 mM MgCl2, 5 mM ethylene glycol 
tetraacetic acid (EGTA) (Sigma-Aldrich), 10 mM HEPES 
at pH 7.3. All recordings were done at room temperature 
(RT; 22–23°C). Tetrodotoxin (TTX; 2 μM) (Alomone 
Labs, Jerusalem, Israel) was used to block sodium currents 
as indicated in Figure 1G. Sodium currents were measured 
at the peak inward current. Potassium currents were mea-
sured at the end of the voltage pulse.
Assay of iPSC-Derived NSC Viability in Cultures 
Exposed to Spinal Cord Lysate
The viability of the cells in culture was assessed under 
the influence of spinal cord lysate, obtained from either 
noninjured rats or rats subjected to spinal cord contu-
sion 7 or 14 days earlier, as explained below. Rats were 
sacrificed, and a spinal cord segment 1 cm long centered 
at the epicenter of the injury (or equivalent segment in 
intact animals) was immediately removed, resuspended 
in Dulbecco’s modified Eagle’s medium (DMEM) 
(Thermo Fisher Scientific), and sonicated for 20 s with 
an Ultrasonic Homogenizer 300 (BioLogics, Grenoble, 
France) to obtain lysate. Quantification of the pro-
tein content was done by the bicinchoninic acid (BCA) 
method (Pierce BCA Protein Assay Kit; Thermo Fisher 
Scientific), and 50 μg protein/ml of lysate was used in the 
experiments.
Cell viability was determined by the tetrazolium salt 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide assay (MTT; Sigma-Aldrich). iPSC-derived NSCs 
(from the same batch as the ones used in the transplanta-
tion experiment, see below) were plated in 96-well cul-
ture plates (Thermo Fisher Scientific) at a density of 2 ´ 
105 cells/ml with Neural Expansion Medium containing 
the supernatant from the injured spinal cord lysate at a 
concentration of 50 μg/ml for 1 to 3 days. Then 10 μl 
of MTT solution (4 mg/ml) was added to each well at a 
final concentration of 0.2 mg/ml. Cells were incubated 
at 37°C for 2 h. After incubation, the medium was aspi-
rated, and 200 μl of dimethyl sulfoxide (DMSO; Sigma-
Aldrich) was added. The absorbance value was measured 
in a multi well spectrophotometer (Bio-Tek, Winooski, 
VT, USA) at 490 and 620 nm.
Spinal Cord Injury
Adult female Sprague–Dawley (SD) rats (9 weeks old, 
250–300 g) were provided by the animal facility of the 
Universitat Autònoma de Barcelona. The animals were 
housed with free access to food and water at RT (22 ± 2°C). 
The experimental procedures were approved by the Ethical 
Committee on Animal Experimentation of the Universitat 
Autònoma de Barcelona and were in accordance with the 
European Communities Council Directive (2010/63/EU).
Operations were performed under ketamine (Imalgene 
1000; Merial, Santiago, Chile) and xylazine (Rompun; 
Bayer DVM, Shawnee Mission, KS, USA) anesthe-
sia [90/10 mg/kg administered via intraperitoneal (IP) 
injection]. A longitudinal dorsal incision was made to 
expose T6–T10 spinous processes. A laminectomy was 
performed in T8–T9 vertebra, and a cord contusion of 
200 kdyn was induced using an Infinite Horizon Impactor 
(Precision Systems and Instrumentation, Lexington, KY, 
USA). A set of six rats were injured to obtain the spinal 
cord lysate for the culture experiment (see above). For the 
transplantation, experimental animals were divided into 
three groups. One group of rats was transplanted acutely, 
at 0 days postinjury (dpi) with iPSC-derived NSCs 
(n = 12). The other two groups of rats were transplanted 
subacutely, at 7 dpi, with vehicle [phosphate-buffered 
saline (PBS); Sigma-Aldrich] (n = 6) and with iPSC- 
derived NSCs (n = 12). Cells that were to be transplanted 
were suspended in PBS at a concentration of 75,000 cells/
ml and kept on ice during the time of the surgery. The 
cell viability at the time of injection was around 90% as 
quantified in a Neubauer chamber (Brand, Wertheim, 
Germany) with trypan blue stain (Sigma-Aldrich). Using 
a glass needle (100-μm internal diameter; Eppendorf, 
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Hamburg, Germany) coupled to a 10-μl Hamilton syringe 
(Hamilton #701; Hamilton Co., Reno, NV, USA), 6 μl 
of the cell suspension or vehicle (PBS) was intraspinally 
injected at the injury epicenter, and 4 μl was injected 
2 mm rostral and caudal to the injured center, for a total 
of 1 ´ 106 cells per rat. A perfusion speed of 2 μl/min was 
controlled by an automatic injector (KDS 310 Plus; KD 
Scientific, Holliston, MA, USA), and the needle tip was 
maintained inside the tissue for 3 min after each injec-
tion to avoid reflux. The wound was sutured and the ani-
mals were allowed to recover in a warm environment. 
Postoperative analgesia was provided with buprenorphine 
(0.05 mg/kg; RB Pharmaceuticals, Berkshire, UK).
In order to prevent immune rejection of the xenogeneic 
grafted cells, immunosuppression was provided. A subcu-
taneous injection of FK506 (Fujisawa Pharmaceuticals, 
Osaka, Japan) was administered immediately after the 
transplantation (2 mg/kg), and additional injections of 
FK506 (1 mg/kg) were given once a day until the end 
of the follow-up to all rats in each experimental group. 
Bladders were expressed twice a day until reflex void-
ing of the bladder was reestablished. To prevent infection, 
amoxicillin (500 mg/L; Laboratorios Normon, Madrid, 
Spain) was given in the drinking water for 1 week.
Functional Assessment
Open-Field Locomotion. Motor behavior was tested 
after surgery once a week until 63 days posttransplant 
(dpt). Animals were placed individually in an open field 
and allowed to move freely for 5 min. Two observers eval-
uated locomotion during open-field walking and scored 
the hindlimb performance, according to the Basso, Beattie, 
Bresnahan (BBB) scale16, ranging from 0 (no movement) 
to 21 (normal movement), and to the BBB subscale17.
Treadmill Locomotion. The maximal walking speed 
was assessed under treadmill conditions once a week, 
starting 2 weeks after injury when the animals were able 
to walk, until 63 dpt. The treadmill speed was progres-
sively increased from 0 cm/s until the animal was not able 
to run with weight support at the selected speed.
Electrophysiological Tests. The rats were anesthetized 
with pentobarbital (30 mg/kg by IP injection; Sigma-
Aldrich), placed prone onto a metal plate, and skin 
temperature was maintained above 32°C. An electromyo-
graph (Sapphire 4ME; Vickers Healthcare Co., Woking, 
UK) was used for the tests. Motor nerve conduction tests 
were performed by stimulating the sciatic nerve with 
single electrical pulses (100 μs at supramaximal inten-
sity) delivered by needles inserted percutaneously at the 
sciatic notch, and recording the compound muscle action 
potentials (CMAPs) of the tibialis anterior (TA) and gas-
trocnemius medialis (GM) muscles by means of needle 
electrodes. The active electrode was inserted on the belly 
of the muscle and the reference at the fourth toe. The peak 
latency and the onset-to-peak amplitude of the maximal 
M waves were measured.
Motor-evoked potentials (MEPs) were elicited by tran-
scranial electrical stimulation of the brain. Two needle 
electrodes were placed subcutaneously over the skull; the 
anode was placed over the sensorimotor cortex, and the 
cathode was placed on the nose. Single electrical pulses 
of supramaximal intensity (25 mA, 100 μs) were applied, 
and the MEPs were recorded with monopolar needle 
electrodes from the TA and GM muscles. The MEP/M 
amplitude ratio was calculated to provide the proportion 
of motor units activated by transcranial electrical stimula-
tion relative to the total pool of spinal motoneurons.
All of the animals were used for functional assess-
ment at different time points. However, animals needed 
for histological study at 7 and 21 dpt (see below) were 
randomly withdrawn from the study at such time points. 
The final numbers of animals considered at different 
times for functional assessment were as follows: vehicle 
group (n = 6 for all the time points), acute transplant group 
FACING PAGE
Figure 1. Characterization of human induced pluripotent stem cells (hiPSCs) and differentiation into neural stem cells (NSCs) and neu-
rons. (A) Photos of retroviral infected fibroblast cells at day 3 postinfection showing high efficiency of transduction based on the polycis-
tronic green fluorescent protein (GFP)-tagged vector. (B) Photographs of hiPSC colony on iHFFs (inactivated human foreskin fibroblasts) 
feeder layer and negative GFP signal demonstrating that the transgene is silenced in the hiPSC clones. Note the good morphology of the 
colony with sharp defined boundaries. (C) Map of the polycistronic retroviral vector containing Oct4, Sox2, Klf4, and c-Myc in a single 
expression vector (GFP tagged). Left panels show pluripotency marker, alkaline phosphatase staining (blue) of 3 of the 18 iPSC clones 
made. (D) Reverse transcription polymerase chain reaction (RT-PCR) gene expression analysis of pluripotency marker Oct4 in three 
hiPSC clones using human embryonic stem cells (hESCs) as a positive control (normalized to 1). All three hiPSCs express high levels of 
Oct4. Transgene expression of Oct4, Sox2, Klf4, and c-Myc was also analyzed to confirm negative GFP signal for all four factors con-
firming that the transgene is switched off in hiPSC clones. (E) Immunofluorescence staining of Oct4 (green) protein expression in hiPSC 
colony. (F) Differentiation to NSCs and neurons. Left: After 1 week in neurobasal medium plus N2/B27 plus RA (1 mM) and stained 
for TUJ1 (green) and MAP2 (red) and 4¢,6-diamidino-2-phenylindole (DAPI) (blue). Middle: After 10 days of differentiation to neurons. 
Right: After 4 weeks, note that a complex neural network of TUJ1/MAP2-positive neurons has formed. (G) Patch clamp analysis. Left: 
Representative traces of voltage-activated Na+ and K+ currents in iPSC-derived neurons recorded with the whole-cell configuration of the 
patch clamp technique. Cells were held at −60 mV, and voltage pulses were applied from −100 to +50 mV to activate the currents. Inset: 
Magnification of the voltage-activated Na+ currents recorded. Right: Application of 2 μM tetrodotoxin significantly blocked inward Na+ 
currents in the recording shown at left but did not affect outward K+ currents. Scale bars: 200 μm (A, B), 100 μm (E, F).
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(n = 12 from 0 to 7 dpi, n = 8 at 14 and 21 dpi, and n = 5 
until the end of the follow-up), and subacute transplant 
group (n = 12 from 0 to 14 dpi, n = 9 at 21 and 35 dpi, and 
n = 6 until the end of the follow-up).
Tissue Processing and Immunohistochemical 
and Histological Analyses
For cell tracking, rats from both acute and subacute 
transplantation groups were sacrificed at 7 (n = 3 for each 
group), 21 (n = 4 for acute and n = 3 for subacute group), 
and 63 days (n = 5 for acute and n = 6 for subacute group) 
after transplantation. Rats were deeply anesthetized 
(pentobarbital, 100 mg/kg IP) and intracardially per-
fused with 4% paraformaldehyde (PFA; Sigma-Aldrich) 
in PBS. The spinal cord segment from 1 cm rostral to 
1 cm caudal of the injury epicenter (2 cm total length) 
was harvested and postfixed in the same fixative solu-
tion for 4 h and cryopreserved in 30% sucrose. Before 
sectioning, macrograph pictures of the spinal cord seg-
ment were obtained under the microscope. For evaluation 
of the spared tissue, grafted area, and cell differentiation, 
transverse spinal cord sections (30 μm thick) were cut 
with a cryotome (Leica CM190; Leica Microsystems, 
Wetzlar, Germany) and distributed in 12 series of 24 sec-
tions (separated by 360 μm) each. Sections were collected 
onto gelatin-coated glass slides.
Spinal cord sections and cell cultures were pro-
cessed for immunohistochemistry (IHC) and immuno-
cytochemistry (ICQ) with specific antibodies for human 
stem cells, including SC121 against cytoplasm protein 
(1:100; Stem Cells Inc., Newark, CA, USA) and SC101 
against nuclear protein (1:500; Stem Cells Inc.) to local-
ize the engrafted cells. Other transverse sections, as well 
as iPSC-derived NSC cultures, were immunostained 
with a primary antibody against glial fibrillary acidic 
protein (GFAP; 1:100; Dako, Glostrup, Denmark; GFAP, 
1:500; Sigma-Aldrich) to visualize astroglial reactiv-
ity and the glial scar around the lesion. To characterize 
the iPSC-derived NSC phenotype after transplantation, 
we used antibodies against NeuN (1:1,000; LifeSpan 
BioSciences, Seattle, WA, USA) and b-III tubulin (1:500; 
BioLegend, San Diego, CA, USA) to label neurons, 
2¢,3¢-cyclic-nucleotide 3¢-phosphodiesterase (CNPase; 
1:100; Merck-Millipore, Darmstadt, Germany) and Ng2 
(1:500; Merck-Millipore) for oligodendrocytes, Ki-67 
(1:100; Abcam, Cambridge, UK) for cells in prolifera-
tion, and nestin (1:500; Covance) to identify iPSC- 
derived NSCs in a nondifferentiated state. To label immune 
cells recruited around the transplant, we used anti-Iba1 
(1:1,000; Wako, Richmond, VA, USA) (primary anti- 
bodies used are summarized in supplementary Table 1, 
available at https://www.dropbox.com/sh/aiaq83057uij1 
c0/AADTehQ_p4b524GALv1H14zya?dl=0). Tissue sec- 
tions were blocked with PBS supplemented with 0.3% 
Triton (Sigma-Aldrich) and 5% species-specific serum 
and incubated for 24 h at 4°C with the corresponding 
primary antibody diluted in PBS plus 0.3% Triton and 
2.5% fetal bovine serum (FBS; Sigma-Aldrich). After 
washes, sections were incubated for 2 h at RT with sec-
ondary antibody (donkey anti-mouse Alexa Fluor 488 
for SC121, SC101, and GFAP; donkey anti-rabbit Alexa 
Fluor 594 for GFAP, b-III tubulin, Ki-67, Ng2, and 
nestin; and goat anti-chicken Alexa Fluor 594 for NeuN 
and CNPase; all at 1:200; Thermo Fisher Scientific) in 
conjunction with 4¢,6-diamidino-2-phenylindole (DAPI; 
1:10,000; Invitrogen, Thermo Fisher Scientific, Carlsbad, 
CA, USA). Slides were dehydrated and mounted with 
Citoseal 60 (Thermo Fisher Scientific). In all IHC pro-
cedures, we included internal controls (for primary and 
secondary antibodies) to detect nonspecific staining.
Table 1. Antibodies Used for Immunolabeling in This Study
Antibody Description Cell Target Host Species Dilution Company
NeuN Neuron-specific nuclear 
protein
Mature neurons Chicken 1:1,000 LifeSpan
BioSciences
b-III tubulin Neural microtubule element Immature neurons Rabbit 1:500 Covance
GFAP Glial fibrilary acidic protein Glial cells Rabbit
Mouse
1:100
1:500
Dako Cytomation 
Sigma
CNPase Constituent of cells that 
elaborate myelin
Mature oligodendrocytes Chicken 1:100 Millipore
Ng2 Proteoglycan of oligoden-
droglial precursors
Immature oligodendrocytes Rabbit 1:500 Millipore
Ki-67 Present during G1, S, G2, 
and M phases
Proliferative cells Rabbit 1:100 Abcam
Nestin Intermediate filament Neural progenitor cells Rabbit 1:500 Covance
SC101 Present in human nuclei Human cells Mouse 1:500 Stem Cells
SC121 Present in human cytoplasm Human cells Mouse 1:100 Stem Cells
Iba1 Calcium binding protein Microglia/macrophages Rabbit 1:1,000 Wako
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Images were obtained with a digital camera (Olympus 
DP50; Olympus, Münster, Germany) attached to a micro-
scope (Olympus BX51). Analysis of spared tissue and graft 
area was made using 36 transversal cord sections (sepa-
rated by 360 mm) of each animal. Consecutive images of 
the SCI segments were taken at 4´ with the same settings. 
The areas of spared tissue, of the cavity, and of the total 
spinal cord section were delineated and measured using 
ImageJ software [National Institutes of Health (NIH), 
Bethesda MA, USA]. Volume of spared tissue was cal-
culated using the Cavalieri’s correction of morphometric 
volume18. A spinal cord segment three-dimensional recon-
struction representative of each group was made using 
the Reconstruct software (http://synapses.clm.utexas.edu/
software-0)19. Analysis of colocalization of the different 
markers was made in transverse cord sections of each ani-
mal. Images of the SCI segments were taken at 10´ with a 
confocal laser microscope by using zen Software (zEISS 
LSM 700; zeiss, Jena, Germany). The area of colocaliza-
tion was measured using the ImageJ software.
Statistical Analysis
Quantitative data of functional and morphological 
studies were analyzed by repeated-measures two-way 
analysis of variance (ANOVA). Bonferroni’s post hoc 
test was used for comparing pairs of groups. In all the 
comparisons, p < 0.05 was considered as significant and 
data are presented as mean ± standard error of the mean 
(SEM). Statistical analyses were performed with Prism 
7 software (GraphPad, La Jolla, CA, USA).
RESULTS
In Vitro Characterization of hiPSC and 
iPSC-Derived NSC Phenotype
hiPSCs were characterized in vitro for pluripotency 
markers, morphology, transgene silencing, and differen-
tiation into neurons (Fig. 1). Retroviral infection of the 
four pluripotency genes into human foreskin fibroblasts 
(HFFs) was performed with very high efficiency (70%), 
and emerging iPSC colonies had a perfect morphology 
with well-defined borders and were negative for trans-
gene activation based on green fluorescent protein (GFP) 
signal after two to three passages (Fig. 1A and B). All 
colonies expressed pluripotency markers for alkaline 
phosphatase and high Oct4 gene expression (Fig. 1C–E). 
Analysis of transgene expression of all four reprogram-
ming factors by reverse transcription polymerase chain 
reaction (RT-PCR) confirmed the negative GFP signal 
that all transgene expressions had been silenced in the 
hiPSC clones. The iPSCs were able to differentiate into 
ectoderm with high efficiency based on TUJ1/MAP2 pro-
tein markers by immunofluorescence analysis (Fig. 1F). 
The iPSCs were also able to differentiate into endoderm 
and mesoderm (data not shown).
iPSC-derived neurons recorded in patch clamp stud-
ies presented small inward currents with activation and 
deactivation properties characteristic of voltage-gated 
Na+ currents (Fig. 1G). Na+ currents started activat-
ing at −30 mV, and mean peak current amplitude was 
−176.5 ± 81.1 pA (n = 4). Bath application of 2 μM TTX 
produced an 80–90% block of the currents, thus assuring 
that these were produced by activation of voltage-gated 
Na+ channels. Outward potassium currents were also seen 
in all cells recorded, with a mean current of 52.8 ± 9.2 pA 
(n = 4). The currents recorded from iPSC-derived neurons 
were of small amplitude compared with primary neurons, 
but they presented the typical characteristics of Na+ and 
K+ voltage-activated currents in neurons. Small ampli-
tudes probably indicate a still low expression of these 
channels at this cell differentiation stage.
Effects of iPSC-Derived NSC Transplantation 
on Functional Recovery After SCI
Open-Field Locomotion. The BBB open-field loco-
motion score was used to test gross voluntary locomo-
tion after SCI. All of the injured rats showed complete 
paralysis of the hind limbs (0 score) at 3 dpi, followed 
by partial recovery during the following 2 weeks. The 
animals achieved a plateau without significant further 
recovery during the next 5 weeks with a BBB score of 
about 10–11 points, indicating weight support and occa-
sional/frequent plantar stepping performance. During the 
early phase, there were only mild differences between 
the group acutely transplanted and the other groups. At 
63 dpt, both acutely and subacutely cell-transplanted 
groups showed a slight, although not significant, 
decrease in the BBB score compared to the vehicle 
group (acute transplant group: 9.83 ± 0.25; subacute 
transplant group: 9 ± 0.14; and vehicle: 10.71 ± 0.34) 
(Fig. 2A). In the BBB subscale (from 0 to 13), which 
measures fine walking ability, both cell-transplanted 
groups had progressively lower scores than the vehicle 
group during the last 5 weeks of the follow-up (at 63 dpt, 
acute transplant group: 0.25 ± 0.17; subacute transplant 
group: 0 ± 0; and vehicle: 1.91 ± 0.96), with significant 
differences between the vehicle and the subacute groups 
(Fig. 2B).
Treadmill Locomotion. Noninjured animals were able 
to run at a maximum treadmill speed of 80 cm/s. In all  SCI 
groups, the rats did not support their weight in stance 
and none were able to run during the first 2 weeks after 
surgery. The acute transplant rats showed a lower speed 
than the subacute group around the 4th week of follow-up 
(at 28 dpt, acute transplant group: 21.1 ± 3.14 cm/s; 
subacute transplant group: 25.2 ± 6.37 cm/s; vehicle: 
27.5 ± 6  cm/s). At later time points there was a decrease 
in the maximal treadmill speed in both treated groups (at 
63 dpt, acute transplant group: 13.3 ± 3.8 cm/s; subacute 
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transplant group: 2 ± 2 cm/s; vehicle: 24.3 ± 4.3 cm/s), 
which was more marked in the subacute group (Fig. 2C).
Motor-Evoked Potentials. The normal MEPs were 
abolished during the follow-up after SCI in most rats, 
and only a few animals presented a very small response 
(<50 μV in amplitude) at the normal latency. A late MEP 
response (latency ~20 ms) appeared after injury in TA 
and GM muscles with increasing amplitude in the vehi-
cle group over time. In contrast, the late MEP responses 
decreased from 28 dpt until the end of the follow-up in 
Figure 2. Effect of iPSC-derived NSC grafts on functional recovery after spinal cord injury (SCI). Open-field locomotion was evalu-
ated weekly after SCI using the score (A) and subscore (B) of the Basso, Beattie, Bresnahan (BBB) scale in the three studied groups. 
All the animals showed complete paralysis of the hindlimbs at 3 days postinjury, followed by a recovery phase reaching a BBB score 
between 9 and 11, and a later decrease of the score in the transplanted groups. Maximum speed that animals were able to walk support-
ing their weight on a treadmill was also measured every week, showing a decrease from 40 days postinjury in the transplanted rats (C). 
Compound muscle action potentials (CMAPs) and motor-evoked potentials (MEPs) from tibialis anterior (TA) and gastrocnemius 
(GM) muscles were recorded every other week starting 2 weeks after injury. The CMAP amplitude (D, top panel) did not change 
during the follow-up (data not shown). Contrarily, the MEP was markedly reduced in amplitude and delayed in latency after injury 
(D, bottom panel) in comparison with noninjured animals (D, middle panel). The ratio MEP/M, used to normalize the evolution of 
the MEP responses (D, graphs), showed an increase over time in nontransplanted animals and a decrease in transplanted rats during 
follow-up. Scales in (D) top and middle recordings: vertical bar = 2 mV, horizontal bar = 2 ms; (D) bottom recording: vertical bar = 
50 μV, horizontal bar = 5 ms. *p < 0.05, **p < 0.01 vehicle (VHC) group versus acute and subacute transplanted groups.
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the cell-transplanted groups compared to the vehicle- 
injected group (Fig. 2D).
Taken together, the data suggest a late reduction of the 
functional recovery achieved during the first weeks after 
transplantation of iPSC-derived NSC-transplanted animals.
iPSC-Derived NSCs Survived and Proliferated 
in the Injured Spinal Cord, Affecting the 
Amount of Spared Tissue
Spinal Cords at 63 Days After Transplantation. After 
SCI, tissue compression occurs as shown in the spi-
nal cord images of vehicle-treated animals. In contrast, 
animals from the cell-transplanted groups demonstrated 
an increase of the volume occupied by the grafted cells 
along the lesion site, which was reflected by the area of 
the spinal cord segment (Fig. 3A).
Spared Tissue After SCI. We then evaluated the amount 
of spared tissue at 63 days after transplantation in trans-
verse cross sections of the spinal cord that were immu-
nostained for GFAP. The amount of preserved tissue was 
significantly higher in areas both rostral and caudal to the 
epicenter in the animals who received vehicle injections 
(Fig. 3B and E) than in those injected with iPSC-derived 
NSCs (Fig. 3C and D). Despite the fact that no significant 
differences were observed between groups at the epicen-
ter of the lesion, the total volume of preserved tissue was 
significantly smaller in the groups transplanted with the 
cells (Fig. 3E).
Grafted Cell Localization and Survival. We evaluated 
the area of spinal cord occupied by iPSC-derived NSCs 
at 7, 21, and 63 dpt along the injured spinal cord seg-
ment. The grafted cells were stained with the human cyto-
plasmic marker SC121 to identify the grafted cells. The 
area occupied by iPSC-derived NSCs was significantly 
larger at 63 dpt than at 7 and 21 dpt in both transplanted 
groups (Fig. 4). Detailed observation of spinal cord cross 
sections showed increasing cell graft volume with time 
in the epicenter and also caudal and rostral to the lesion 
(supplementary Fig. 3A–F; available at: https://www.drop 
box.com/sh/aiaq83057uij1c0/AADTehQ_p4b524GALv 
1H14zya?dl=0).
Immune Cell Recruitment Around iPSC-Derived NSC 
Transplant. We evaluated the presence of immune cells in 
the cell graft at 63 dpt by using an antibody against Iba1. 
We observed recruitment of microglia and monocytes at 
the edge and in the middle of the graft in both groups of 
transplanted animals (supplementary Fig. 4A–C; avail-
able at: https://www.dropbox.com/sh/aiaq83057uij1c0/A 
ADTehQ_p4b524GALv1H14zya?dl=0).
iPSC-Derived NSC Proliferation. In order to assess 
proliferation, we stained the transplanted cells with the 
human nuclear marker SC101 and the proliferation marker 
Ki-67 in samples taken at 7, 21, and 63 dpt (Fig. 5A). By 
confocal microscopy, we observed colocalization of both 
markers (Fig. 5B). The percentage of area occupied by 
Ki-67 in relation to the total area occupied by SC101 
indicated that iPSC-derived NSCs in the spinal cords 
showed higher proliferation at 7 dpt compared to 21 and 
63 dpt (Fig. 5C).
iPSC-Derived NSC Differentiation Within the 
Injured Spinal Cord
Phenotype of iPSC-Derived NSCs Before Transplanta-
tion. iPSC-derived NSCs were cultured in vitro and stained 
with a combination of differentiation markers to character-
ize their phenotype at passage 3, just before transplanta-
tion. Other cells from the same culture and passage were 
used for in vivo transplantation. Immunohistochemical 
analysis in vitro showed that iPSC-derived NSCs at pas-
sage 3 expressed nestin, b-III tubulin, and Ki-67, but no 
expression of the markers NeuN, GFAP, CNPase, and 
Ng2 was observed (supplementary Fig. 1A–L; available 
at: https://www.dropbox.com/sh/aiaq83057uij1c0/AADTe 
hQ_p4b524GALv1H14zya?dl=0), indicating that before 
grafting, the cells maintained a neural stem and prolifera-
tive phenotype.
Transplanted iPSC-Derived NSC Phenotype. Spinal 
cord sections from the transplanted groups were immu-
nostained with a combination of differentiation markers. 
We observed that some iPSC-derived NSCs, identified by 
labeling with the human markers SC101 or SC121, were 
also positive for GFAP, Nestin, NeuN, and b-III tubulin, 
but no colocalization with either CNPase or Ng2 was 
observed (supplementary Fig. 2A–F; available at: https://
www.dropbox.com/sh/aiaq83057uij1c0/AADTehQ_p4b 
524GALv1H14zya?dl=0). We then measured the per-
centage of colocalized area of these markers in spinal cord 
sections at 7, 21, and 63 dpt in both transplanted groups. 
Regarding the expression of the neural marker b-III tubu-
lin (Fig. 6), the percentage of colocalized area with SC121 
increased significantly from 7 dpt (acute iPSC-derived 
NSC transplant group: 71.31 ± 2.30%; subacute iPSC-
derived NSC transplant group: 59.9 ± 2.05%) to 63 dpt 
(acute transplant group: 85.60 ± 2.75%; subacute trans-
plant group: 88.08 ± 1.78%) in both transplanted groups. 
Similarly, the colocalized area of the neural marker NeuN 
with the human marker SC101 was significantly higher 
at 63 dpt (acute transplant group: 15.70 ± 9%; subacute 
transplant group: 30.55 ± 10%) than at 7 (acute transplant 
group: 3.17 ± 3%; subacute transplant group: 0.30 ± 0%) 
or 21 dpt (acute transplant group: 5.13 ± 2%; subacute 
transplant group: 6.95 ± 2%) in both groups (Fig. 6A–D). 
Regarding glial phenotype markers, measurements of 
iPSC-derived NSCs expressing the astroglial marker 
GFAP showed differences between the center and the 
edge of the graft (Fig. 7). In the middle of the graft, we 
observed a slight increase of cells from 7 (acute transplant 
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Figure 3. The spared tissue at the end of the follow-up was reduced by the cell graft. Representative photographs of spinal cords at 
63 days after cell grafting showing an enlargement at the injury site in the iPSC-derived NSC-transplanted groups compared with the 
vehicle-injected group (A). The spared tissue was measured in transversal sections of the injured spinal cord segment immunostained 
for GFAP. A decrease of the preserved area was observed at 63 days posttransplant (dpt) in the epicenter of the lesion and rostrocau-
dally in both transplanted groups in comparison with the vehicle group (B, vehicle; C, acute; D, subacute). Quantification of the area 
of spared tissue, expressed as percentage of the total cross section area, along 1 cm of injured spinal cord in the studied groups, and 
percentage of spared tissue volume in the same segment (E). *p < 0.05, ***p < 0.001. At 63 dpt: acute (n = 5), subacute (n = 6), and 
vehicle (n = 6).
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group: 11 ± 4%; subacute transplant group: 21.58 ± 5%) 
to 21 dpt (acute transplant group: 21.79 ± 9%; subacute 
transplant group: 23.97 ± 1%), whereas the expression 
of GFAP increased significantly from 7 and 21 to 63 dpt 
(acute transplant group: 38.82 ± 7%; subacute transplant 
group: 48.46 ± 6%) in both transplanted groups. On 
the other hand, SC121 and GFAP colocalization in 
the periphery of the graft increased significantly only 
from 21 dpt (acute transplant group: 25.01 ± 2%; sub-
acute transplant group: 17.32 ± 4%) to 63 dpt (acute 
Figure 4. Grafted cell survival and localization in the injured spinal cord. The amount of grafted cells along 1 cm of the injured spinal 
cord was studied at 7, 21, and 63 dpt by immunolabeling with human marker SC121 (A–F). The grafted cells occupied the main part 
of the spinal cord at 63 dpt, filling an area that was significantly increased compared to the area at 7 and 21 days (G, H). ***p < 0.001. 
Acute and subacute transplanted groups: at 7 dpt (n = 3), 21 dpt (n = 4), and 63 dpt (n = 6).
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transplant group: 37.30 ± 4%; subacute transplant group: 
32.79 ± 4%) (Fig. 7A–D). Differentiation of the iPSC- 
derived NSCs into astrocytes was observed at earlier 
time in the graft edge than in the center of the graft. As 
mentioned above, we did not observe expression of oligo-
dendrocyte markers, CNPase or Ng2, in the grafted iPSC-
derived NSCs at any time throughout the study. Moreover, 
we observed that in both cell-transplanted groups, around 
40% of the cells were positive for nestin, suggesting that 
these cells remained undifferentiated (Fig. 8).
These results indicate that grafted iPSC-derived 
NSCs were able to survive and proliferate within the 
injured tissue. Moreover, the cells were able to express 
neuronal and astroglial phenotypes. Most of the NSCs 
differentiated into neurons, but only a low proportion 
were mature neurons, indicating that iPSC-derived 
NSCs were unable to fully differentiate in the lesion 
site of SCI rats. The expression of Nestin suggests that 
almost half of the transplanted cells were at a nondif-
ferentiated stage, which could explain their continued 
proliferation (Fig. 8).
The SCI Environment Induces iPSC-Derived 
NSC Proliferation In Vitro
In order to analyze further how the spinal cord micro-
environment can affect the iPSC-derived NSC pheno type, 
the cells were cultured in vitro with the addition of protein 
lysate from intact or injured spinal cord. It is worth noting 
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Figure 6. Expression of neuronal markers by grafted iPSC-derived NSCs. Confocal image colocalization of the human markers 
(SC121 and SC101) and the neuronal markers b-III tubulin (A) and NeuN (B) at 7, 21, and 63 dpt in both acute and subacute trans-
planted groups. b-III tubulin expression increased significantly from 7 and 21 dpt to 63 dpt (C, D). NeuN expression was significantly 
increased at 63 dpt compared to 7 and 21 dpt (C, D). *p < 0.05, **p < 0.01. Scale bar: 100 μm. Acute and subacute transplanted groups: 
at 7 dpt (n = 3), 21 dpt (n = 4), and 63 dpt (n = 6).
Figure 5. iPSC-derived NSCs still proliferate within the spinal cord at 63 days after transplantation. iPSC-derived NSCs immuno-
stained with the proliferation marker Ki-67 and the human nuclear marker SC101 in transverse sections of the injured spinal cord at 
7, 21, and 63 dpt in both transplanted groups (A). The orthogonal view from confocal image shows colocalization between both mark-
ers (B). The amount of colocalization between Ki-67 and SC101 was measured as the percentage of the Ki-67 area coincident with 
the SC101 area. The results indicated significantly higher proliferation at 7 dpt compared to 21 and 63 dpt in both groups (C). The 
number of SC101-Ki-67-positive cells decreased with time, but at the end of the follow-up, there were still proliferating grafted cells. 
**p < 0.01, 0 dpi group versus 7 dpi group; &p < 0.05, &&&p < 0.001, 21 and 63 dpt versus 7 dpt. Scale bar: 50 μm. Acute and subacute 
transplanted groups: at 7 dpt (n = 3), 21 dpt (n = 4), and 63 dpt (n = 6).
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Figure 7. GFAP expression by grafted iPSC-derived NSCs. Colocalization of glial fibrillary acidic protein (GFAP) with human SC121 
marker at the middle (A) and at the edge (B) of the graft at 7, 21, and 63 dpt. The expression of GFAP significantly increased from 7 
and 21 dpt to 63 dpt in the middle (C, D), and from 21 to 63 dpt in the periphery (C, D). *p < 0.05, **p < 0.01. Scale bar: 100  μm. Acute 
and subacute transplanted groups: at 7 dpt (n = 3), 21 dpt (n = 4), and 63 dpt (n = 6).
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that during the spinal cord extraction, there is an unavoid-
able damage to the cord tissue due to ische mia and the dis-
section process. Therefore, what we here name as “intact” 
spinal cord lysate is in fact an injury niche by itself, but 
without a previous lesion. By confocal microscopy we 
observed that some of the iPSC-derived NSCs were 
positive for nestin (Fig. 9E–H) and Ki-67 (Fig. 9I–L), 
indicating that the cells remained nondifferentiated and 
in a proliferative state for 3 days under the influence of 
the injured spinal cord lysates. Moreover, b-III tubulin- 
positive cells were found (Fig. 9A–D), indicating that 
some of the iPSC-derived NSCs were able to differen-
tiate into nonmature neural lineage cells at 3 days after 
plating, independently of the type of extract added 
to the culture. The MTT cell viability assay (Fig. 9M) 
showed that iPSC-derived NSCs in the presence of lysate 
from intact, 7- and 14-dpi spinal cords had a significant 
increase in proliferation, compared to control cultures 
without extract (Fig. 9I–L). The lysate from previously 
injured spinal cords had increased MTT activity during 
the first day in vitro in comparison with lysate from the 
intact spinal cord. In contrast, lysates from previously 
injured spinal cords produced significantly less iPSC- 
derived NSC proliferation than the lysate from intact cords 
at 2 and 3 days in culture. This could be due to changes in 
the proliferative capacity of the cells exposed in vitro to 
injured spinal cord lysate over time or to detrimental fac-
tors that provoke major cell death. These results suggest 
that the injured spinal cord environment contains factors 
that induce proliferation of iPSC-derived NSCs without 
changes in their immature stage.
DISCUSSION
The generation of human NSCs from iPSCs may be 
a promising cell source for autologous transplantation in 
the treatment of SCI20. hiPSC-derived NSCs have been 
transplanted after SCI in mice, rats, and marmosets, pro-
moting functional recovery in some cases13. However, 
other studies have demonstrated that there are impor-
tant differences in tumorigenicity and responsiveness to 
neural induction signals of iPSCs derived from various 
somatic tissues. For instance, transplanted mouse embry-
onic iPSC clone-derived NSCs were able to differentiate 
into neurospheres and showed good survival, differentia-
tion into neurons, astrocytes, and oligodendrocytes, and 
posttransplantation safety in the lesion site of an SCI 
mouse model without teratoma formation. On the other 
hand, transplanted adult mouse tissue (tip tail fibroblasts)-
derived iPSCs showed resistance to differentiation, and 
most of the cells remained in an undifferentiated stage, 
even after the protocol for inducing differentiation11. In 
this case, teratoma formation was observed. These con-
tradictory findings suggest that iPSCs derived from adult 
tissue are not as safe as iPSCs derived from embryonic 
tissue21. Unfortunately, the use of human embryos as a 
source comes with difficulty in generating patient-spe-
cific ESCs and ethical controversies that hinder their 
clinical application. Therefore, research efforts are now 
focused on the use of iPSCs derived from adult somatic 
cells to establish a cell source that allows the autologous 
transplantation of patient-specific cells22,23. Nowadays, 
most reprogramming techniques rely on the factors 
Oct4, Sox2, Klf4, and c-Myc (referred to as OSKM), and 
Figure 8. Nestin expression of the grafted iPSC-derived NSCs at the end of the follow-up. The colocalization of the nestin marker 
with the human SC121 marker was analyzed at 63 dpt in both groups that received the cell transplant acutely (at 0 dpi) or subacutely 
(at 7 dpi) (A). Around 40% of the SC121-positive iPSC-derived NSC area was also positive for nestin (B). No significant difference 
was observed between groups. Scale bar: 200 μm. At 63 dpt: acute and subacute transplanted groups (n = 6).
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various methods are used for their delivery into cells, 
which are divided into viral21 and nonviral methods24,25. 
However, they entail some risks that could be avoided by 
using synthetic mRNA transfection of the four factors, 
removing c-Myc26. Another possible source of cells is 
from direct reprogramming somatic cells, bypassing the 
pluripotent stages; in vivo conversion of astrocytes into 
neurons in injured adult spinal cords and further matura-
tion have been shown in mice27.
In order to analyze how the SCI environment affects the 
survival and differentiation pattern of adult hiPSC-derived 
NSCs, we transplanted them into the spinal cord of rats 
after a contusion injury. It is important to note that vehicle 
was used as a control instead of nonviable cells. The aim of 
the transplantation study was to test the effect of the cells, 
regardless of the vehicle used for transplantation. Nonviable 
cells could change the spinal cord environment due to spe-
cific reactions against them, making it difficult to conclude 
Figure 9. In vitro iPSC-derived NSCs’ response after incubation with a lysate of intact and injured spinal cord. Cells were positive for 
b-III tubulin (A–D), nestin (E–H), and Ki-67 (I–L). The viability test showed an increase of cell proliferation (M) in the presence of 
the injured cord lysate at 7 dpi. ***p < 0.001, control versus addition of lysates; &p < 0.05, intact versus 7 and 14 dpi lysates; #p < 0.05, 
7 dpi versus 14 dpi lysates. Scale bar: 50 μm. Intact (n = 3), 7 dpi (n = 3), and 14 dpi (n = 3).
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if the differences between groups were produced by the 
vehicle or the presence of cells (alive or not). Our results 
reveal that the grafted cells grew and expanded inside of 
the injured spinal cord, filling the cavity but also affecting 
spared tissue. This was associated with a decrease of func-
tional recovery of the transplanted SCI animals at the late 
phase. This observation could be related to the number of 
cells that remained undifferentiated and in a proliferative 
stage until late time points after transplantation.
Adult hiPSC-Derived NSCs Proliferated Inside the 
Injured Tissue Compromising Functional Recovery
In the present study, we found that the grafted iPSC-
derived NSCs were able to expand through the injury site 
over time, indicating that the injury niche allows the main-
tenance of a proliferative state. Similarly, the cord injury 
niche enhanced iPSC-derived NSC proliferation in vitro, 
suggesting that the production of soluble factors induces 
proliferation early after injury. These results are in agree-
ment with the higher amount of Ki-67-positive iPSC-de-
rived NSCs 1 week after grafting in rats transplanted on the 
same day (0 dpi) than in rats with delayed (7 dpi) transplant. 
Similar results were reported by Sontag et al., who found 
that human NSCs propagated as neurospheres proliferated 
more between 1 and 28 dpt than later, between 28 and 98 
dpt, in the injured spinal cord27. It is worth noting that while 
the in vitro experiments showed an increase in cell number 
without apparent changes in Ki-67 expression, in the in vivo 
experiments the number of proliferating cells decreased 
with time. The partial differentiation and maturation of the 
cells after transplantation may explain the reduction in the 
amount of proliferative cells. A previous study showed that 
the expansion pattern of fetal brain tissue-derived hNSCs 
after transplantation changes depending on the distance 
from the epicenter of the lesion at long time points27. The 
same study also demonstrated that the transplantation niche 
and the injured microenvironment have effects on the spa-
tiotemporal dynamics of hNSC engraftment, similar to 
what we found with our NSCs derived from adult iPSCs. 
Since we transplanted human NSCs into rat spinal cords, 
rats were treated with FK506, an immunosuppressive drug 
that prevents immunological rejection against the grafted 
cells28. Therefore, we cannot dismiss the possibility that the 
immunosuppression favored the proliferation of the trans-
planted cells. Nevertheless, with the low dose of FK506 
administered, there was still some degree of microglial 
reaction against the grafted cells (see supplementary Fig. 4; 
available at: https://www.dropbox.com/sh/aiaq83057uij1c0/
AADTehQ_p4b524GALv1H14zya?dl=0). Other studies 
in SCI using histocompatible approaches of iPSC-derived 
NSC transplantation also showed tumorigenic-like activity 
of the grafted cells11. The high proliferation of the iPSC-de-
rived NSCs at short time points and the low but continuous 
proliferation at longer time points explain the overgrowth of 
grafted tissue, forming a cell mass inside the injured and 
transplanted spinal cords. The teratogenic activity of our 
iPSC-derived NSCs may be a consequence of the repro-
gramming of adult somatic cells11,29, which seems not to 
happen with hNSCs obtained directly from adult spinal 
cord donors30.
The expansion of the grafted iPSC-derived NSCs in the 
injured spinal cord resulted in an enlargement of the vol-
ume of damaged tissue with a decrease of spared tissue. The 
200-kdyn contusion injury leads to a drastic destruction of 
the spinal cord parenchyma at the epicenter and extends 
along several segments, interrupting most motor descend-
ing tracts, as demonstrated by the abolition of MEPs and 
marked locomotor deficits. Interestingly, functional recov-
ery of the transplanted animals was similar or slightly bet-
ter than that of vehicle-injected rats during the early phase 
of the follow-up. However, around 4–6 weeks after trans-
plantation, the performance of the animals transplanted 
with iPSC-derived NSCs showed a progressive decline, 
reflected by a reduction in the BBB subscore, the running 
capacity, and the MEP amplitude. At the end of the study, 
histological analysis showed that the transplanted groups 
had less residual tissue at ventral and lateral regions of 
the cord than vehicle-injected animals, thereby explaining 
the decrease in the locomotor score of engrafted rats with 
time. The explanation for this late functional reduction in 
transplanted animals is likely the progressive increase of 
the cell mass inside the injured cord.
Contrary to our findings, some previous studies with 
hiPSC-derived NSCs have shown some functional bene-
fits in the transplanted animals. Therefore, it is important 
to consider the differences between studies. Regarding 
the source of NSCs, the derivation protocol of neural lin-
eage cells from iPSCs may be crucial to obtain different 
NSCs. For instance, some studies have used the NSC cul-
ture system in neurospheres, which is composed of free-
floating clusters of NSCs. The neurosphere passage can 
determine the fate of the NSCs, since the differentiation 
of primary neurospheres is mainly into neurons, whereas 
secondary neurospheres mature into a mixed population 
of neurons, astrocytes, and oligodendrocytes8. Therefore, 
although Nori et al.2 and Kobayashi et al.9 used a simi-
lar contusion model to in our study, they transplanted 
iPSC-derived NSCs from tertiary neurospheres with a 
later determination period than our adherent cells. This 
suggests that adult cells are more vulnerable to changes 
induced by the injured environment than fetal cells, even 
though a recent study claims that the use of NSCs com-
ing from aged fibroblasts might not be a limiting factor22. 
Furthermore, the use of certain factors during repro-
gramming may enhance neurite outgrowth, maturation, 
and expression of different neural markers31, influencing 
engraftment and differentiation within the injured ner-
vous system32.
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Another important difference between study designs 
is the type of SCI lesion used. A recent study has shown 
that NPCs transplanted after spinal cord contusion into 
immunocompetent mice exhibited poor cell survival, 
even when mice were under immunosuppressive ther-
apy. Moreover, the transplant did not promote functional 
recovery12. On the contrary, Romanyuk et al. reported 
that neural progenitors derived from iPSC are able to 
survive, engraft, migrate, and differentiate within the 
damaged rat spinal cord after a balloon-induced com-
pression lesion, inducing also functional recovery of 
the transplanted animals13. Different lesion models may 
provoke different types of damage in the spinal cord, 
which will be an important determinant for the engraft-
ment of the cells in the tissue.
The SCI Environment Does Not Induce Full 
Differentiation of Adult iPSC-Derived NSCs
The main goal for NSC transplantation after CNS 
injuries is the restitution of neural cells and the connec-
tivity between cells that is destroyed by the SCI lesion. 
For this purpose, appropriate differentiation and inte-
gration of the cells in the host tissue are needed. Before 
transplantation, our cells exhibited a neural stem/pro-
genitor-like phenotype. However, once transplanted, 
iPSC-derived NSCs differentiated along the neural 
lineage, expressing a high percentage of b-III tubulin 
(~85%) and a lower percentage of NeuN (20–40%) at 
late time points. This means that most of the grafted cells 
had an immature neuronal phenotype (b-III tubulin+/
NeuN−) at 2 months after grafting. Differentiation into 
astrocytes was also observed. Although our cells were 
mostly b-III tubulin positive, it has been shown that cer-
tain nestin-positive astrocytes derived from human fetal 
astrocytes can also express low levels of b-III tubulin33, 
but this coexpression with the astroglial marker, GFAP, 
is mainly observed in early proliferative stages, prior 
to differentiation34. Therefore, the b-III tubulin/nestin-
positive cells (before transplant) could be NSCs with 
progenitor potential to produce astrocytes and neurons 
or could be a mixture of predestined neurons and astro-
glial progenitors indistinguishable with the markers we 
used. Interestingly, temporal and spatial differentiation 
of iPSC-derived NSCs into astrocytes was observed. 
The higher number of GFAP-positive cells in the exter-
nal part than in middle areas of the graft at early time 
points suggests that the close contact with the lesion 
induces stronger proliferation of astrocytes. In normal 
conditions, in the surrounding area of the SCI, there is 
high astrocyte reactivity, which contributes to formation 
of the glial scar35. The lower differentiation of iPSC-
derived NSCs into astrocytes in the middle of the graft 
could be a consequence of the absence of contact with 
factors coming from the lesion border and might also 
explain the differentiation of the transplanted cells into 
neurons instead of astrocytes in this part of the graft.
The differentiation pattern of the NSCs within the 
injured tissue seems to be important for determining the 
effects of the transplanted cells on recovery after SCI. 
The presence of only a few fully mature and functional 
neurons at the time of behavioral assessment of the ani-
mals is one of the causes of poor functional benefits after 
transplantation22. Moreover, in cases where NSCs and 
NPCs were directly cultured from an adult human spi-
nal cord, transplanted neurospheres in the rat spinal cord 
after injury generated neurons, astrocytes, and oligoden-
drocytes, suggesting specific phenotypic potential related 
to the donor species30. This study also showed absence of 
Ki-67-positive cells at 1 week posttransplantation, indi-
cating that grafted cells became postmitotic. These results 
suggest that cells coming from specific organs have more 
complete differentiation into the neural lineage cells than 
those coming from iPSCs. Therefore, the cell source as 
well as the injured environment are crucial for the fate of 
the transplanted cells26.
CONCLUSIONS
Taken together, the results obtained suggest that b-III 
tubulin/nestin-positive iPSC-derived NSCs were able to 
differentiate into neuronal and astroglial lineages once 
transplanted, but, despite the high percentage of differen-
tiated cells, there was still a proportion of cells that per-
sisted in a neural stem or progenitor stage. The sustained 
proliferative state of these cells explains the uncontrolled 
growth of the cell graft within the injured spinal cord and 
the decrease in functional recovery of the transplanted ani-
mals. Moreover, results from in vitro and in vivo experi-
ments suggest that the niche of transplantation and the 
injured microenvironment affects the differentiation pattern 
and spatiotemporal dynamics of the iPSC-derived NSCs27. 
Concerning the source of the NSCs, either from embryonic 
or from adult cells, we verified that NSCs reprogrammed 
from adult somatic cells have a potential risk for the for-
mation of a tumor-like mass in the graft. Therefore, new 
experimental approaches are needed to promote and guide 
cell differentiation, as well as reduce tumorigenicity once 
the cells are transplanted within the lesion site36.
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